The majority of these compounds are engineered in order to prevent antibody-dependent cell cytotoxicity (ADCC), but Avelumab, an anti-PD-L1 IgG1 isotype, is able to perform both immune checkpoint inhibition and ADCC so that TAMs, MDSCs, and Treg, which can express high levels of PD-L1 in the tumor infiltrate, can be targeted as well as cancer cells (35, 138, 139). The gene discussed is CD274; the disease is neoplasm.